An open-label, phase III study to evaluate the efficacy and safety of MRA [tocilizumab] in patients with RA [rheumatoid arthritis]
Phase of Trial: Phase III
Latest Information Update: 03 Jun 2016
At a glance
- Drugs Disease-modifying antirheumatics; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms SAMURAI
- Sponsors Chugai Pharmaceutical
- 01 Sep 2007 Results have been published.
- 01 Sep 2007 Trail name and acronym added.
- 13 Aug 2007 Status changed from in progress to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History